Italy's Clinical Research System Faces Critical Challenges in Innovation and Sustainability

Italy boasts a substantial clinical and scientific infrastructure, including numerous hospitals, specialized outpatient clinics, and research institutes, supported by a highly skilled workforce. However, the nation faces structural challenges in converting this potential into systemic competitiveness, attracting investment, and ensuring swift access to innovation. This is particularly evident in clinical research, a critical component of pharmaceutical innovation.

While Italy has historically ranked among the top European countries for clinical trials and possesses internationally recognized centers of excellence, especially in oncology, it is now falling behind. The country currently ranks fourth in Europe for clinical trials conducted in recent years, trailing Spain, France, and Germany. This decline mirrors a broader European trend, with a 50% drop in cancer clinical studies over a decade, while China has seen a significant increase. Spain, in particular, has adopted more coordinated policies and created a more favorable regulatory and administrative context.

The specific weaknesses in Italy's system are costly. Study activation times remain longer than those of key competitors. Initiating trials at centers is often delayed by complex and non-standardized administrative procedures. This uncertainty discourages international investment. Furthermore, Italy struggles to effectively translate research into innovation, especially in precision medicine. Despite high scientific output and patent growth, the system faces difficulties in technology transfer, capital attraction, and developing an advanced industrial sector. Consequently, Italy excels at generating knowledge but falters in its subsequent development and industrialization phases.

“

The Italian system does not suffer from a lack of skills or basic resources, but in its ability to function quickly, coherently, and value-oriented.